# The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Study · id `cardio:ct-nct05033964` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05033964](<https://clinicaltrials.gov/study/NCT05033964>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05033964

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05033964. Randomized; single masking; primary purpose treatment. Start 2021-12-15 (actual); primary completion 2022-12-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05033964, source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)
- Started: 2021-12-15 (actual) (ClinicalTrials.gov record NCT05033964, source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)
- Primary completion: 2022-12-02 (actual) (ClinicalTrials.gov record NCT05033964, source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)
- Completion: 2026-03 (anticipated) (ClinicalTrials.gov record NCT05033964, source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)
- Countries: Belgium; Brazil; Czechia; Netherlands; New Zealand (ClinicalTrials.gov record NCT05033964, source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05033964-2024-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
- Condition: Coronary Artery Disease
- Intervention (Combination product): Percutaneous Coronary Intervention with drug eluting stents
- Lead sponsor: Elixir Medical Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Elixir Medical Corporation (`cardio:org-elixir-medical-corporation`)

## Provenance

Content hash: a8122b74620c75e264d8edfca692f117419df217ec34208a2dbd54f9c5eccc93
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
